GRAYZEL DAVID S.

Sociétés où GRAYZEL DAVID S. a négocié

• Q32 Bio Inc.12 tx · $79.5K · Jul 21, 2026
• Jade Biosciences, Inc.14 tx · $21.2M · Jun 7, 2024
• Surface Oncology, Inc.12 tx · $46M · Sep 8, 2023

Historique de performance de GRAYZEL DAVID S.

Historique insuffisant pour un historique de performance statistique (moins de 5 achats sur le marché).

Historique des transactions de GRAYZEL DAVID S.

Co-initiés de GRAYZEL DAVID S.

• Iwicki Mark TJade Biosciences, Inc. +1
• NOVARTIS AGQ32 Bio Inc. +1
• Novartis Institutes for BioMedical Research, Inc.Q32 Bio Inc. +1
• 5AM Co-Investors IV, L.P.Q32 Bio Inc.
• 5AM Partners IV, LLCQ32 Bio Inc.
• 5AM Ventures IV, L.P.Q32 Bio Inc.
• Adams ChandraSurface Oncology, Inc.
• Alloway PaulQ32 Bio Inc.
• ARCH Venture Fund VIII, L.P.Q32 Bio Inc.
• ARCH Venture Fund VIII Overage, L.P.Q32 Bio Inc.
• ARCH Venture Partners VIII, LLCQ32 Bio Inc.
• ARCH Venture Partners VIII, L.P.Q32 Bio Inc.
• Atlas Venture Associates IX, LLCSurface Oncology, Inc.
• Atlas Venture Associates IX, L.P.Surface Oncology, Inc.
• Atlas Venture Associates Opportunity III, LLCQ32 Bio Inc.
• Atlas Venture Associates Opportunity III, L.P.Q32 Bio Inc.
• Atlas Venture Associates Opportunity II, LLCQ32 Bio Inc.
• Atlas Venture Associates Opportunity II, LPQ32 Bio Inc.